Lava Therapeutics Nv Expected To Post A Loss Of 14 Cents A Share: Earnings Preview

LAVA Therapeutics NV

11/11/2022 16:58

* LAVA Therapeutics NV  LVTX.OQ   LVTX.O  is expected
to show a
rise in quarterly revenue when it reports  results on November
14 (estimated). 
    * The Utrecht-based  company is expected to report  a
472.6% increase in revenue to €10.2 million from €1.78 million a
year ago, according to the mean estimate from 5 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for LAVA Therapeutics
NV is
for a loss of 14 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for LAVA
Therapeutics
NV is $20​, above​ its last closing price of $4.87. ​​​

Previous quarterly performance (using preferred earnings measure
in euros). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.59       -0.59      -0.31     Beat    47.3
 Mar. 31 2022  -0.79       -0.81      -0.41     Beat    49.4
 Dec. 31 2021  -0.37       -0.36      -0.38     Missed  -5.6​
 Sep. 30 2021  -0.28       -0.27      -0.23     Beat    13.3
 ​​Jun.        -0.23       -0.23      -0.23     Met     -0.8
 30 2021                                                
 Mar. 31 2021  -0.67       -0.67      -10.19    Missed  -1,432
                                                        .3​
 This summary was machine generated November 11 at 16:58 GMT. 
All figures in euros  unless otherwise stated